Tarsus Pharmaceuticals (TARS) Interest Expenses (2022 - 2026)

Tarsus Pharmaceuticals' Interest Expenses history runs 5 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 3.84% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $8.8 million (down 2.52% YoY), while the FY2025 annual figure was $8.9 million, up 13.84% from the prior year.
• Interest Expenses was $2.1 million for Q1 2026 at Tarsus Pharmaceuticals, down from $2.2 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $2.4 million in Q3 2024 to a low of $316000.0 in Q1 2022.
• Historically, Interest Expenses has averaged $1.4 million across 5 years, with a median of $989000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Interest Expenses surged 184.97% in 2024, then declined 7.24% in 2025.
• A 5-year view of Interest Expenses shows it stood at $692000.0 in 2022, then surged by 42.92% to $989000.0 in 2023, then soared by 133.77% to $2.3 million in 2024, then slipped by 4.24% to $2.2 million in 2025, then slipped by 3.88% to $2.1 million in 2026.
• The last three Interest Expenses figures came in at $2.1 million (Q1 2026), $2.2 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.